Consolidation cetuximab after concurrent triplet radiochemotherapy+cetuximab in patients with advanced head and neck cancer: A randomized phase II study.

Publication

Consolidation cetuximab after concurrent triplet radiochemotherapy+cetuximab in patients with advanced head and neck cancer: A randomized phase II study.

Journal Paper/Review - Jun 12, 2020

Riesterer Oliver, Pruschy Martin, Bender Sabine, Sharma Ashish, Bogowicz Marta, Tanadini-Lang Stephanie, Stieb Sonja, Bertogg Kaja, Weber Sandra, Ikenberg Kristian, Huber Gerhard, Schmid Stephan, Bredell Marius, Veit-Haibach Patrick, Rordorf Tamara, Held Ulrike, Glanzmann Christoph, Studer Gabriela

Citation

Riesterer O, Pruschy M, Bender S, Sharma A, Bogowicz M, Tanadini-Lang S, Stieb S, Bertogg K, Weber S, Ikenberg K, Huber G, Schmid S, Bredell M, Veit-Haibach P, Rordorf T, Held U, Glanzmann C, Studer G. Consolidation cetuximab after concurrent triplet radiochemotherapy+cetuximab in patients with advanced head and neck cancer: A randomized phase II study. Radiother Oncol 2020; 150:62-69.

Type

Journal Paper/Review (English)

Journal

Radiother Oncol 2020; 150

Publication Date

Jun 12, 2020

Issn Electronic

1879-0887

Pages

62-69

Brief description/objective

Preclinical data suggest that cetuximab should be continued after end of concurrent radiotherapy+cetuximab due to its efficacy against residual tumor cells in the irradiated tumor bed. Based on this concept the phase II add-on cetuximab (AOC) study was designed.